Patent · US Active

Human rhinovirus vaccine

US11040095B2 · kind B2 · utility

0Cited by

1References

15Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Catherine Gerard · Sint-Genesius-Rode, BE
Sandra Giannini · Rixensart, BE
Julien Thierry Massaux · Rixensart, BE

Key dates

Filing date	Oct 5, 2017
Grant date	Jun 22, 2021
Priority date	—
Expiry date	Oct 5, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/32734
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.